Blocknomi
TLDR IONS stock slides 2.23% to $42.93 despite Roche’s Phase 3 kidney trial success. Roche’s sefaxersen cuts proteinuria 43.1% in a key Phase 3 kidney disease trial. Ionis shares rebound…
Related articles
-
Hackers Jailbreak iPhone 18 Pro on Stage, and It Survives a Reboot
Decrypt Published 16.10.2026 19:36
-
Europol Warns Quantum Threat Could Put Crypto Fortunes at Risk
Bitcoin.com Published 07.10.2026 21:05
-
Ripple-Backed Evernorth Secures Major Deal Ahead of Nasdaq Listing: Why Is XRP Price Still Down?
U.Today Published 10.10.2026 13:05
-
ApeCoin Price Tests Support Ahead of New York ApeFest Meetup
Cryptonews Published 06.10.2026 08:52
-
Nebius Stock Surges as Truist Reaffirms $355 Target After AI Selloff
The Crypto Basic Published 19.10.2026 12:37
-
Bitcoin Trails Its Typical October Path by Nearly 10 Percentage Points as Mid-Month Weakness Takes Hold
The Crypto Basic Published 16.10.2026 07:58
-
Micron (MU) Analysts See 88% Upside Despite Minor Pullback Following Record Fiscal 2026
Blocknomi Published 06.10.2026 10:19
-
Eco upgrades stablecoin API with quoted settlement or automatic refunds
Crypto.News Published 14.10.2026 13:00